Welcome to The Prescription. Though we may not have a permanent FDA commissioner, the agency is still sending out Untitled Letters — including to one drugmaker that is all too familiar with these missives.
Health and wellness takeaways from Kantar’s 2026 BrandZ report
Top Story
Content in this email has expired.
Additional Stories
Content in this email has expired.
Creative Inspiration
Content in this email has expired.
Quote of the Day
“I think the way Senator Cassidy handled the Kennedy nomination was a lose-lose proposition,” said John Couvillon, a pollster and political consultant for Louisiana state treasurer and Senate candidate John Fleming. Source.
Key Data Point
Content in this email has expired.
Partner Content
Content in this email has expired.
5 Things for Pharma Marketers to Know Today
What brought down former Food and Drug Administration commissioner Marty Makary. Even though he’s out of the top spot, the agency chaos is still in. (Los Angeles Times)
Iran War disruptions are starting to hit pharma’s supply chain. Evonik is raising prices in response to higher energy costs and other suppliers are weighing their own moves as upstream pressure builds around chemicals, materials and manufacturing inputs. (Endpoints News)
A rare gene therapy fear just got more real. Scientists linked a boy’s brain tumor to the viral delivery system used in his gene therapy, a finding doctors say underscores a theoretical cancer risk that still has to be weighed against potentially life-changing benefits. (STAT News)
The hantavirus outbreak response has raised pandemic readiness concerns. Public health experts say the response underscored vulnerabilities tied to the U.S. withdrawal from the World Health Organization, as well as layoffs and leadership turnover at federal agencies like the Centers for Disease Control and Prevention. (Axios)
Eli Lilly is pitching lower-dose Zepbound as the forever plan. New data suggest patients may be able to maintain weight loss on smaller doses of Zepbound, while Lilly is also positioning Foundayo as part of the long-term obesity care play. (Benzinga)
Get access to key industry news, analysis and insights anytime, anywhere with your MM+M subscription — FREE to qualified subscribers! You’ll receive: special reports and features, the Agency 100 issue, daily newsletters and exclusive invites to industry events!
Interested in Sponsoring? mmmsales@haymarketmedia.com
